$0.40 EPS Expected for Acorda Therapeutics, Inc. (NASDAQ:ACOR) This Quarter
Equities research analysts expect that Acorda Therapeutics, Inc. (NASDAQ:ACOR) will report earnings per share of $0.40 for the current quarter, according to Zacks Investment Research. Six analysts have made estimates for Acorda Therapeutics’ earnings, with the lowest EPS estimate coming in at $0.21 and the highest estimate coming in at $0.51. Acorda Therapeutics reported earnings of ($0.28) per share in the same quarter last year, which suggests a positive year over year growth rate of 242.9%. The business is scheduled to announce its next quarterly earnings report on Thursday, October 26th.
According to Zacks, analysts expect that Acorda Therapeutics will report full year earnings of $0.43 per share for the current financial year, with EPS estimates ranging from $0.04 to $0.73. For the next financial year, analysts expect that the company will post earnings of ($0.49) per share, with EPS estimates ranging from ($1.33) to $1.21. Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that cover Acorda Therapeutics.
Acorda Therapeutics (NASDAQ:ACOR) last released its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.29 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.13 by $0.16. Acorda Therapeutics had a negative return on equity of 6.37% and a negative net margin of 8.02%. The firm had revenue of $139.40 million during the quarter, compared to analysts’ expectations of $139.81 million. During the same period last year, the firm posted $0.07 EPS. The business’s revenue was up 9.3% on a year-over-year basis.
A number of equities analysts have recently issued reports on the stock. BidaskClub raised shares of Acorda Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Friday, July 7th. Cowen and Company reissued an “outperform” rating and set a $35.00 price objective on shares of Acorda Therapeutics in a research report on Wednesday, June 7th. J P Morgan Chase & Co set a $24.00 price objective on shares of Acorda Therapeutics and gave the stock a “hold” rating in a research report on Tuesday, June 6th. TheStreet cut shares of Acorda Therapeutics from a “c-” rating to a “d+” rating in a research report on Monday, April 24th. Finally, Stifel Nicolaus reissued a “buy” rating on shares of Acorda Therapeutics in a research report on Friday, July 28th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $25.26.
Acorda Therapeutics (NASDAQ ACOR) traded up 4.40% during midday trading on Friday, reaching $21.35. The company had a trading volume of 432,186 shares. The firm has a 50-day moving average of $20.82 and a 200-day moving average of $20.34. The stock’s market cap is $995.76 million. Acorda Therapeutics has a 12 month low of $13.60 and a 12 month high of $33.00.
In related news, Director Lorin Randall sold 10,000 shares of the firm’s stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $21.66, for a total value of $216,600.00. Following the transaction, the director now owns 10,000 shares of the company’s stock, valued at approximately $216,600. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Andrew A. Hindman sold 7,704 shares of the firm’s stock in a transaction dated Monday, May 15th. The shares were sold at an average price of $15.75, for a total transaction of $121,338.00. Following the completion of the transaction, the insider now directly owns 46,123 shares in the company, valued at approximately $726,437.25. The disclosure for this sale can be found here. In the last ninety days, insiders sold 27,704 shares of company stock worth $553,638. 7.90% of the stock is owned by insiders.
Institutional investors have recently made changes to their positions in the stock. C WorldWide Group Holding A S acquired a new position in shares of Acorda Therapeutics during the first quarter valued at $106,000. State of Alaska Department of Revenue boosted its position in shares of Acorda Therapeutics by 2.6% in the first quarter. State of Alaska Department of Revenue now owns 5,120 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 130 shares during the last quarter. Hikari Power Ltd acquired a new position in shares of Acorda Therapeutics during the first quarter valued at $210,000. Mason Street Advisors LLC boosted its position in shares of Acorda Therapeutics by 7.7% in the first quarter. Mason Street Advisors LLC now owns 10,852 shares of the biopharmaceutical company’s stock valued at $228,000 after buying an additional 775 shares during the last quarter. Finally, Municipal Employees Retirement System of Michigan boosted its position in shares of Acorda Therapeutics by 3.9% in the second quarter. Municipal Employees Retirement System of Michigan now owns 10,960 shares of the biopharmaceutical company’s stock valued at $216,000 after buying an additional 410 shares during the last quarter.
Acorda Therapeutics Company Profile
Acorda Therapeutics, Inc is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Acorda Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.